Can-Fite BioPharma Ltd. (CANF) News
Track canonical SquawkNews coverage tagged to CANF, Can-Fite BioPharma Ltd.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 26 indexed stories across 13 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
CANF: Longer-than-expected survival in liver cancer and narrowed net loss mark H1 2026 results
Longer-than-expected survival in the pivotal liver cancer study and durable outcomes in pancreatic cancer highlight clinical progress. Net loss narrowed to $4.60 million for H1 2026, with stable revenues and increased R&
EARNINGS | Sep 14, 2026, 10:03 PM UTC
L
Can-Fite says namodenoson improved decompensated cirrhosis outcomes
Can-Fite BioPharma reported patient resolution of ascites and regression of esophageal varices with namodenoson, with clinical stability for about 28 months before a successful liver transplantation.
GEOPOLITICS | Sep 09, 2026, 11:03 AM UTC
L
CANF - Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantatio
CANF - Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
EQUITY | Sep 09, 2026, 11:02 AM UTC
L
Can-Fite reports Q2 2026 results and Phase III liver cancer update
Can-Fite reports Q2 2026 financial results and ongoing clinical progress in its pivotal Phase III liver cancer study.
EARNINGS | Sep 08, 2026, 12:27 PM UTC
L
Can-Fite announces warrant exercise raising about $4.0 million gross proceeds
Can-Fite (CANF) said warrants were exercised for approximately $4.0 million in gross proceeds.
EQUITY | Sep 02, 2026, 01:02 PM UTC
M
Can-Fite plans interim analysis advance in Phase III liver cancer study
Can-Fite said it plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma, after reporting overall survival longer than anticipated in the ongoing pivotal Phase III.
GEOPOLITICS | Sep 02, 2026, 11:07 AM UTC
L
CANF - Can-Fite: Namodenoson Enhances the Anti- Cancer Effect of Chemotherapy in Pancreatic Cancer
CANF - Can-Fite: Namodenoson Enhances the Anti- Cancer Effect of Chemotherapy in Pancreatic Cancer
EQUITY | Aug 17, 2026, 11:00 AM UTC
M
CANF Advances Phase III Drug Candidates
CANF advances FDA and EMA regulatory status of its Phase III drug candidates
EQUITY | Aug 12, 2026, 11:00 AM UTC
M
Can-Fite Submits Phase 2 Study Protocol
Can-Fite submits phase 2 study for piclidenoson
EQUITY | Aug 03, 2026, 11:54 AM UTC
M
Can-Fite Launches Piclidenoson Program
Can-Fite starts clinical program for rare disease
EQUITY | Aug 03, 2026, 11:00 AM UTC
L
CANF Can Fite Biofpharma Ltd. - Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and P
CANF Can Fite Biofpharma Ltd. - Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
EQUITY | Jul 14, 2026, 11:17 AM UTC
H
Can-Fite BioPharma Completes Enrolment Of First 247 Patients In Pivotal Phase 3 Study Evaluating Piclidenoson For Treatment Of Moderate-To-S
Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE: CANF ) (TASE: CANF), a clinical-stage biotechnology company devel
GEOPOLITICS | Jul 06, 2026, 11:06 AM UTC
L
HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Can Fite Biopharma (AMEX: CANF ) with a Buy and raises the price target from $5 to $8.
EQUITY | Jul 02, 2026, 10:59 AM UTC
L
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Can Fite Biopharma (AMEX: CANF ) shares rose 43.8% to $4.27 during Wednesday's regular session. The company's market cap stands at $6.3 million. Regencell Bioscience (NASDAQ: RGC ) stock moved upwards by 35.79% t
EQUITY | Jul 01, 2026, 05:05 PM UTC
L
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Can Fite Biopharma (AMEX: CANF ) stock moved upwards by 52.0% to $4.52 during Wednesday's pre-market session. The company's market cap stands at $6.3 million. Atlantic International (NASDAQ: ATLN ) shares rose 17
EQUITY | Jul 01, 2026, 12:05 PM UTC
L
Can-Fite Biopharma shares are trading higher after the company announced that its Phase 2a study evaluating Namodenoson in patients with adv
Can-Fite Biopharma shares are trading higher after the company announced that its Phase 2a study evaluating Namodenoson in patients with advanced pancreatic ductal adenocarcinoma achieved its primary safety endpoint and
EQUITY | Jul 01, 2026, 12:00 PM UTC
L
CanFite Reported Namodenoson In Predominantly Third-Line Pancreatic Cancer Patients Demonstrated Durable Survival Despite Advanced Disease;
CanFite Reported Namodenoson In Predominantly Third-Line Pancreatic Cancer Patients Demonstrated Durable Survival Despite Advanced Disease; Second-Line Patient Remains Alive More Than 18 Months
EQUITY | Jul 01, 2026, 11:04 AM UTC
M
12 Health Care Stocks Move
Gainers Universe Pharmaceuticals (NASDAQ: UPC ) stock moved upwards by 168.2% to $7.94 during Friday's after-market session. The market value of their outstanding shares is at $1.8 million. Tvardi Therapeutics (NASDAQ: T
EQUITY | Jun 26, 2026, 11:20 PM UTC
H
Small Caps Surge
Several small cap stocks are experiencing significant gains premarket due to various positive news announcements.
EQUITY | Jun 26, 2026, 01:08 PM UTC
L
Top Small Cap Positive News Movers Premarket: INLF: +75% Momentum Mover ILLR: +50% Momentum Mover ZDAI: +50% Momentum Mover SDOT: +46% Momen
Top Small Cap Positive News Movers Premarket: INLF: +75% Momentum Mover ILLR: +50% Momentum Mover ZDAI: +50% Momentum Mover SDOT: +46% Momentum Mover IVF: +43% Momentum Mover QUCY: +35% Approves Acquisition of Equity Sta
MNA | Jun 26, 2026, 12:13 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Friday's pre-market session, with gainers including Quantum Cyber and INVO Fertility, and losers including Creative Medical Tech and Omeros
EQUITY | Jun 26, 2026, 12:05 PM UTC
M
CANF Secures Patent
Can-Fite secures Japanese patent allowance for Namodenoson's anti-obesity technology
EQUITY | Jun 26, 2026, 11:00 AM UTC
M
CANF: Publishes Article
Can-Fite BioPharma publishes peer-reviewed article on therapeutic potential of lead drug candidates Piclidenoson and Namodenoson
EQUITY | Jun 22, 2026, 11:15 AM UTC
L
CANF Publishes Article
Can-Fite publishes peer-reviewed article on therapeutic potential of Piclidenoson and Namodenoson
EQUITY | Jun 22, 2026, 11:02 AM UTC